ImmuCell Corporation — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; comparative figures are for 2022. The filing was signed April 1, 2024. ImmuCell develops and sells animal-health products, principally First Defense, which prevents scours in newborn calves. Re-Tain, a proposed treatment for subclinical mastitis in dairy cows, remained under development and had no commercial sales.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Product sales | $17.47 million | $18.57 million |
| Gross margin | $3.87 million; 22% | $7.65 million; 41% |
| Operating loss | $5.75 million | $2.30 million |
| Net loss | $5.77 million; $0.75 per share | $2.49 million; $0.32 per share |
| Cash used in operating activities | $4.67 million | $1.54 million |
| Capital expenditures | $1.89 million | $3.98 million |
- Sales fell 6%, primarily because production shortfalls constrained supply; First Defense represented 99% of product sales.
- Gross margin contracted sharply as production slowed, fixed costs were spread over fewer units, and contamination and other process losses led to $527,000 of inventory write-offs (versus $589,000 in 2022). Excluding those write-offs, management estimated gross margin at approximately 25% in 2023 and 44% in 2022.
- At year-end, cash was $979,000, inventory $7.81 million, total assets $43.81 million, and stockholders’ equity $24.99 million. Net working capital was $7.27 million, down from $10.92 million.
- Debt, net of issuance and discount costs, was approximately $12.0 million, compared with $10.2 million in 2022; the reported blended fixed interest rate was 4.51%. Principal and interest payments were expected to total approximately $2.0 million in each of 2024 and 2025. A $1.0 million revolving credit line had no year-end balance.
- Management stated that cash and expected gross margin from ongoing product sales should fund planned working capital, capital expenditures, and operations for at least 12 months from the filing date. This depends on sales and production performance.
Material changes and operating developments
- Three production contamination events during 2022–2023, along with a freeze-dryer repair, required slower production and remediation. The resulting First Defense backlog rose from approximately $2.5 million at year-end 2022 to $9.4 million at year-end 2023 and $10.3 million on March 8, 2024. The company cautioned that aged, duplicate, or cancellable orders may make the backlog an imperfect indicator of future sales.
- Management estimated First Defense annual production capacity at approximately $30 million, with recent output improving; November–December 2023 production annualized to about $26.8 million. It aims to produce at least $6 million of finished goods per quarter. Capacity estimates depend on yields, product mix, and other factors.
- First Defense sales in the fourth quarter were $5.10 million, up 30% from $3.91 million in fourth-quarter 2022; fourth-quarter gross margin was $1.26 million, or 25%, versus $992,000, or 25%.
- Cash declined by $4.81 million during 2023. Financing cash flow included $3.0 million of new term-loan proceeds, partly offset by principal repayments; investing cash flow was primarily capital spending.
- The company raised First Defense prices by an average of 8% effective November 15, 2023 and reported that the order backlog did not decline after the increase.
Outlook, risks, and unusual items
- Management aims to exceed 2023 product sales of approximately $17.5 million as soon as possible and has a longer-term goal of exceeding $35 million in annual product sales as soon as possible within four years after Re-Tain’s market launch. These are objectives, not guaranteed guidance.
- Re-Tain requires FDA approval before sales. Four of five major technical sections had been completed; the CMC section remained outstanding. After a November 2023 resubmission, management expected an FDA response by May 2024. The filing said a favorable CMC completion could still leave roughly ten months for review, administrative review, and launch preparation. An early-2024 FDA facility inspection identified one deficiency, to which the company reported responding.
- Initial Re-Tain distribution is planned as a controlled launch over 18–24 months. Supply is constrained by dependence on contract manufacturer Norbrook for aseptic filling; the company paused roughly $2 million of planned in-house filling investment. Management anticipates a possible supply gap after initial launch inventory is consumed and before an alternative manufacturing source is approved.
- Debt-service covenant compliance has been waived for specified periods, including the period ending June 30, 2024. A minimum debt-service coverage ratio of 1.35 applies thereafter under the disclosed schedule; failure to meet requirements or obtain further relief could affect borrowing terms and liquidity.
- The company recorded $365,000 of insurance recovery income in 2023. It had received $250,000 toward a separate $750,000 business-interruption claim; the remaining claim was under insurer review, and recovery was uncertain.
- Other key risks include continued contamination or equipment problems, customer loss from prolonged shortages, inflation and supply constraints, dependence on two distributors (79% of 2023 sales), and reliance on First Defense and the dairy and beef markets. The USDA temporarily stopped distribution and sale of First Defense in July 2023; the restrictions were rescinded in early August, allowing shipments to resume.
- Management reported that a material weakness involving inventory depreciation capitalization, identified in the second quarter, was remediated in the third quarter; management concluded controls were effective at year-end. The independent auditor issued an unqualified opinion on the financial statements and identified inventory valuation as a critical audit matter. No material legal proceedings or reportable subsequent events were disclosed.
Most important facts for investors to verify
- Whether production quality remains stable, quarterly output reaches management’s target, and the $10.3 million reported backlog converts into shipments and sales.
- FDA review and approval timing for Re-Tain, including CMC and facility status, and whether a dependable post-launch aseptic-filling source is secured.
- Cash consumption, debt-service capacity, covenant waivers and compliance, and the impact of planned rent and capital commitments on liquidity.
- Actual gross-margin recovery after the 2023 production disruption, including yield trends, contamination losses, price realization, and inventory valuation.
- Collection and customer concentration risks, and the outcome of the pending insurance claim.